Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) will host a conference call on May 13, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a corporate update. The company is developing Haduvio™ (nalbuphine ER) for serious neurologically mediated conditions, including chronic pruritus associated with prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis patients. Haduvio is currently undergoing Phase 2b/3 clinical trials. An archived replay of the conference call will be available on Trevi's website.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will participate in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, with a presentation at 2:15 p.m. ET. The company focuses on developing Haduvio™ (nalbuphine ER) for serious neurologically mediated conditions. Investors can access a live webcast on the company's website, along with an archived replay available for 30 days post-conference. Trevi is conducting clinical trials for Haduvio targeting chronic pruritus, chronic cough in idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its Q4 2020 and annual financial results, reporting a net loss of $9.5 million for Q4 and $32.8 million for the year. R&D expenses rose to $22.3 million, driven by clinical trial activities. The company is progressing in its Phase 2b/3 PRISM trial, expecting to complete enrollment of 360 subjects by Q3 2021, with top-line data anticipated in Q4 2021. As of December 31, 2020, Trevi had $45 million in cash, expected to fund operations into Q2 2022.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a conference call on March 25, 2021, at 4:30 p.m. ET to discuss its corporate update and financial results for the year ended December 31, 2020. The company is focused on developing Haduvio (nalbuphine ER) for serious neurologically mediated conditions. Currently, Trevi is conducting a Phase 2b/3 clinical trial for chronic pruritus and a Phase 2 trial for chronic cough related to idiopathic pulmonary fibrosis. The company is also planning a Phase 2 study for treating levodopa-induced dyskinesia in Parkinson’s patients.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, featuring a virtual fireside chat at 4:20 p.m. ET. The event will also include virtual investor meetings. Live webcasts can be accessed on the company's website, with a replay available for 30 days post-conference. Trevi is focused on the development of Haduvio (nalbuphine ER) for treating serious neurologically mediated conditions, including chronic cough and pruritus, currently conducting clinical trials for these indications.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announces the appointment of William Forbes as Chief Development Officer, effective immediately. Dr. Forbes, a seasoned professional with over 30 years in pharmaceutical product development, will oversee the clinical development of Haduvio™ (nalbuphine ER) for conditions like chronic pruritus and cough. Forbes previously held leadership roles at Vivelix Pharmaceuticals and Salix Pharmaceuticals, contributing to 12 FDA approvals. Trevi aims to fulfill unmet medical needs through Haduvio, currently in late-stage clinical trials.
Trevi Therapeutics (TRVI) reported updates on its clinical trials and financial results for Q3 2020. The PRISM trial for Haduvio, targeting severe pruritus, has surpassed halfway enrollment with approximately 190 subjects. The company aims to complete enrollment by Q3 2021 and report data by Q4 2021. In a phase 2 trial for chronic cough in IPF, new patient enrollment has resumed post COVID-19. As of September 30, 2020, Trevi's cash position was $53.3 million, expected to fund operations into H1 2022, with a Q3 net loss of $7.4 million.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 10:00 a.m. ET. The management will provide a company overview and conduct virtual investor meetings. Interested parties can access a live webcast of the presentation on Trevi's website, with an archived replay available for 30 days post-conference. Trevi Therapeutics focuses on developing Haduvio™, an investigational oral formulation of nalbuphine, aimed at treating serious neurologically mediated conditions like chronic pruritus.
Trevi Therapeutics (Nasdaq: TRVI) announces a conference call on November 11, 2020, at 4:30 p.m. ET to discuss Q3 2020 financial results and provide a corporate update. The call can be accessed by phone or via a live audio webcast on the company's website. Haduvio™ (nalbuphine ER), the company's lead drug, is being developed for serious neurologically mediated conditions, including chronic pruritus and levodopa-induced dyskinesia. Currently, Trevi is conducting a Phase 2b/3 trial, PRISM, for patients with severe pruritus.
Trevi Therapeutics, Inc. (TRVI) has resumed patient screening for its Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) after a pause due to COVID-19. The trial aims to enroll 60 subjects and investigate the efficacy of nalbuphine ER in reducing cough frequency. Additionally, the Phase 2b/3 PRISM trial for Haduvio in severe pruritus has reached 50% enrollment, with expectations to finish by Q3 2021 and report data by Q4 2021. The regulatory approval for protocol amendments enhances patient safety during the pandemic.